Stocks · Health care · Pharmaceutical Preparations

Aktis Oncology, Inc.

AKTS
United States Fiscal year ends December CIK 0002035832 Results filed 13 Aug 2026

What the insiders did Net buying

By person

10 insiders · 20 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
EcoR1 Capital, LLC entity
Director
$40.00M (2)
—
+$40.00M
347,305
$7.30M
—
Ansbert Gadicke
10% owner
$20.03M (1)
—
+$20.03M
10,260,064
$215.78M
+2,903%
Mpm Bioventures 2018, L.p.
10% owner
$20.03M (1)
—
+$20.03M
10,260,064
$215.78M
+2,903%
Helen Susan Kim
Director
$15.03M (2)
—
+$15.03M
157,387
$3.31M
—
Vida Ventures II, LLC entity
10% owner
$15.03M (2)
—
+$15.03M
157,387
$3.31M
—
Todd Foley
Director
$4.19M (1)
—
+$4.19M
4,235,403
$89.07M
—
Akos Czibere
Chief Medical Officer
—
$1.65M (5) scheduled
−$1.65M
0
$0.00
—
Shulamit Ron-Bigger
Chief Operating Officer
—
$1.39M (3) scheduled
−$1.39M
0
$0.00
—
Ken Herrmann
Director
—
$196.53K (3) scheduled
−$196.53K
0
$0.00
—
Lloyd Mitchell Segal
Director
—
—
—
19,631
$412.85K
—

No percentages here. This company's share count has moved by a factor of 58.4 over the window, from 915,261 to 53,446,222 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.